Lyell immunopharma investor relations
WebLyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024. Cash, cash equivalents and marketable securities of $710.3 million as of December 31, 2024 supports advancing robust pipeline into 2026, through multiple clinical milestones Phase 1 clinical trials initiated for two wholly-owned ... Web8 dec. 2024 · The Investor Relations website contains information about Lyell Immunopharma, Inc.'s business for stockholders, potential investors, and financial analysts. ... Investors. Lyell is a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors.
Lyell immunopharma investor relations
Did you know?
Web30 sept. 2024 · --Lyell Immunopharma, Inc.,, a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported third quarter 2024 financial results and provided ... Web17 mar. 2024 · Ellen Rose has been working as a Investor Relations Senior VP, Communications at Lyell Immunopharma for 2 years. Lyell Immunopharma is part of the Business Services industry, and located in California, United States.
WebLyell Immunopharma has raised a total of $493M in funding over 2 rounds. Their latest funding was raised on Mar 12, 2024 from a Series C round. Lyell Immunopharma is registered under the ticker NASDAQ:LYEL . Their stock opened with $17.00 in its Jun 16, 2024 IPO. Lyell Immunopharma is funded by 4 investors. WebFind the latest Earnings Report Date for Lyell Immunopharma, Inc. Common Stock (LYEL) at Nasdaq.com.
Web16 dec. 2024 · About Lyell Immunopharma, Inc. Lyell is a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. ... Communications and Investor Relations erose@lyell ... Web11 apr. 2024 · Lyell Immunopharma Inc., whose market valuation is $613.91 million at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.26 per share this quarter, however they have predicted annual earnings per share of ...
WebLyell Immunopharma, Inc. 注册地: 美国 注册地详细地址: 美国特拉华州 成立日期: 2024-06 总股数: 249325627 董事长: Richard D. Klausner: 员工总数: 274 所属行业: 生物科技 主要电话: 1-650-6950677 主要传真 - 公司网站: www.lyell.com: 电子邮箱-主要办公地址 chris cooley jersey numberWebir.lyell.com genshin rollsWebLegal Name Lyell Immunopharma, Inc. Number of Exits 1. Stock Symbol NASDAQ:LYEL. Company Type For Profit. Phone Number 1 650-695-0677. Lyell is a T cell … genshin rosalia buildWebAcum 23 ore · Lynn Seely, M.D. – President and CEO of Lyell Immunopharma; Dennis Slamon, M.D., Ph.D. – Co-Founder; TD Cowen acted as exclusive placement agent for the Series B financing. Crandon Law LLC served as counsel to TORL BioTherapeutics LLC. Latham & Watkins LLP. served as counsel to Goldman, Sachs & Co. LLC. About TORL … genshin rosalineWebLyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer. ... Their most recent investment was on Mar 31, 2024, when Outpace Bio raised $30M. Date Company Name Round Money Raised Industry Lead Investor; Mar 31, 2024: Outpace Bio: Series A: $30M chris cooley nfl statsWebJoin to apply for the Executive Assistant II role at Lyell Immunopharma. First name. Last name. Email. Password (8+ characters) ... and the SVP of Communications and Investor Relations. The ideal ... genshin rollingWebMEDTRONIC PLC : Presentación de la compañía MEDTRONIC PLC, accionistas, dirección, descripción del negocio, calificaciones financieras, comunicados de prensa oficiales, detalles de contacto y códigos de la bolsa de valores MDTD ARDEUT111283 Buenos Aires Stock Exchange chris cooley first wife